With our CELx Signaling Function tests, clinicians will be able to make, for the first time, treatment decisions based on patient-specific functional cellular analysis prior to prescribing a drug. Our goal is to provide clinicians with the most complete diagnosis possible to they can select the best targeted therapy for their patient, and make it the first therapy they prescribe.
We also work in partnership with pharmaceutical companies to develop companion diagnostics (CDx) for investigational or approved drugs seeking new indications. Our CDx tests will give pharmaceutical developers the opportunity to narrow the patient populations for their investigational therapies to include only those patients most likely to benefit. This will allow the design of clinical trials with larger effect sizes, smaller sample sizes and faster completion times, thus increasing trial success rate while lowering development costs.